Iovance Biotherapeutics, Inc.
IOVA Healthcare Biotechnology
Iovance Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $263.5 million, up 60.6% from fiscal 2024. In the quarter to June 2026, revenue grew 65.7%, EPS grew 66.7% and free cash flow grew 11.5%, each against the same quarter a year earlier.
Follow IOVA
Iovance Biotherapeutics, Inc. (IOVA) EV/Sales
As of 16 October 2026, Iovance Biotherapeutics, Inc. (IOVA) trades at a EV/Sales of 17.9×. Over the past ten years it has ranged from 0.0× (March 2024) to 1,798× (April 2024); the current reading is higher than 93% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.6× | (76.78%) |
| FY2024 | 11.1× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.9× | 19.77% |
| Mar 2026 | 4.0× | 57.01% |
| Dec 2025 | 2.6× | 31.76% |
| Sep 2025 | 2.0× | 71.80% |
| 9 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BLTE Belite Bio, Inc. Sponsored ADR compare | n/m |
| IMVT Immunovant, Inc. compare | n/m |
| KOD Kodiak Sciences Inc. compare | n/m |
| IONS Ionis Pharmaceuticals, Inc. compare | 7.8× |
| IOVA Iovance Biotherapeutics, Inc. | 17.9× |
| LGND Ligand Pharmaceuticals Incorporated compare | 19.8× |
| RYTM Rhythm Pharmaceuticals, Inc. compare | 23.3× |
| PRAX Praxis Precision Medicines, Inc. compare | 735× |
| SYRE Spyre Therapeutics, Inc. compare | 5,336× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)